Rupatadine: A review of its use in the management of allergic disorders

Drugs

Volumn 67, Issue 3, 2007, Pages 457-474

  Keam, Susan J ^a,b   Plosker, Greg L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Allergic rhinitis; Chronic idiopathic urticaria; Histamine H1 receptor antagonist; Pharmacodynamics; Pharmacokinetics; Rupatadine; Therapeutic use

Indexed keywords

ALERGOLIBER; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; CYTOCHROME P450 3A4; DECONGESTIVE AGENT; DESLORATADINE; EBASTINE; ERYTHROMYCIN; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; PLACEBO; RINIALER; RUPATADINE; RUPAX; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; IN VITRO STUDY; NONHUMAN; NOSE ALLERGY; PHARYNGITIS; PSYCHOMOTOR ACTIVITY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SOMNOLENCE; URTICARIA; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-ALLERGIC AGENTS; CYPROHEPTADINE; DRUG INTERACTIONS; HUMANS; HYPERSENSITIVITY; PLATELET ACTIVATING FACTOR; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

ANIMALIA; CITRUS X PARADISI;

EID: 33947310075     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767030-00008     Document Type: Review

References (58)

1. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): in collaboration with the World Health Organization. Allergy 2002; 57 (9): 841-55
2. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004 Sep; 114 (3): 465-74
3. Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4 (5): 297-305
4. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515-36
5. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28 (12): 1101-18
6. Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005 Dec; 39 (12): 2056-64
7. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006 Oct; 7 (14): 1989-2001
8. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55 (2): 116-34
9. Dykewicz MS, Fineman S, Skoner P, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5 Pt 2): 478-518
10. 2LEN). Allergy 2006 Sep; 61 (9): 1086-96
11. 2LEN/EDF guideline: management of urticaria. Allergy 2006 Mar; 61 (3): 321-31
12. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108 (2): S65-71
13. Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006 Nov; 118 (5): 985-96
14. Hennino A, Bérard F, Guillot I, et al. Pathophysiology of urticaria. Clin Rev Allergy Immunol 2006 Feb; 30 (1): 3-11
15. Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000; 55 Suppl. 64: 34-9
16. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997 Jan; 280 (1): 114-21
17. García-Rafanell J. Rupatadine fumarate: antiallergic, histamine and PAF antagonist. Drugs Fut 1996 Oct; 21 (10): 1033-6
18. Uriach J, Cia SA. Rupafin 10mg comprimidos (rupatadina): resumen de las características del producto [online]. Available from URL: http://www.msc.es/profesional/farmacia/informaMedicamentos/doc/ F_TecnicaNum64053.doc [Accessed 2004 Feb 3]
19. Merlos M, Balsa D, Giral M, et al. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues [abstract no. PA-95]. Methods Find Exp Clin Pharmacol 1997; 19 Suppl. A: 148
20. Giral M, Balsa D, Ferrando R, et al. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor and histamine [abstract no. P321]. Allergy 1998; 53 Suppl. 43: 131-2
21. 1 receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003 Jun; 39 (6): 451-68
22. Queralt M, Brazis P, Merlos M, et al. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res 1998; 44 (2-3): 49-55
23. Queralt M, Brazís P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res 2000 Jul; 49 (7): 355-60
24. Queralt M, Merlos M, Giral M, et al. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res 1996; 39 (1): 12-8
25. Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in guinea pigs [abstract no. P-21]. Methods Find Exp Clin Pharmacol 1996; 18 Suppl. B: 140
26. Merlos M, Giral M, Balsa D, et al. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized guinea pigs [abstract no. 904]. J Allergy Clin Immunol 1998 Jan; 101 (Pt 2): S218
27. Stuebner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006 Jan; 96 (1): 37-44
28. Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers [abstract no. PB-62]. Methods Find Exp Clin Pharmacol 1997; 19 Suppl. A: 189-203
29. Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production [abstract no. 1175]. Allergy Clin Immunol Int 2005; Suppl. 1: 427
30. Taglialatela M, Annunziato l. Evaluation of the cardiac safety of second-generation antihistamines. Allergy 2000; 55: 22-30
31. Caballero R, Valenzuela C, Longobardo M, et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999 Nov; 128 (5): 1071-81
32. Izquierdo I, Pérez I, Villa M. Lack of electrocardiographic effects of Rupatadine, new nonsedating selective histamine H1-receptor and PAF antagonist [abstract no. 637]. Allergy 2001; 56 Suppl. 68: 212
33. Ramis I, Giral M, Nieto C, et al. Lack of cardiotoxic effects of rupatadine in isolated Purkinje fibres and its relationship with rupatadine cardiac levels [abstract no. 947]. Allergy 2000; 55 Suppl. 63: 264
34. Giral M, Merlos M, Balsa D, et al. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines [abstract no. 110]. Allergy 1997; 52 Suppl. 37: 44
35. E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH Harmonised Tripartite Guideline. Current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005 May 12 [online]. Available from URL: http://www.ich.org [Accessed 2006 Nov 16]
36. Donado E, Pérez I, García O, et al. Cardiac safety of rupatadine according to the new ICH guideline: a "thorough QT/QTc study" [abstract no. 760 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10-14; Vienna
37. Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004; 50 (4): 311-21
38. Vuurman E, Theunissen E, van Oers A. Lack of effects between rupatadine 10mg and placebo on actual driving performance of healthy volunteers. Human Psychopharmacol Clin Exp. In press
39. Barbanoj MJ, García-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 2006 Jan; 21 (1): 13-26
40. Solans A, Merlos M, Antonijoan R, et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin: a randomized, crossover, multiple-dose open study [abstract no. 410]. Allergy Clin Immunol Int 2005; Suppl. 1: 159
41. Izquierdo I, Paredes I, Lurigados C, et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis [abstract no. 984]. Allergy 2000; 55 Suppl. 63: 275
42. Pérez I, De la Cruz G, Villa M, et al. Rupatadine in allergic rhinitis: pooled analysis of efficacy data [abstract no. 784]. Allergy 2002; 57 Suppl. 73: 245
43. Saint-Martin F, Dumur JP, Pérez I, et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004; 14 (1): 34-40
44. Guadaño EM, Serra-Batlles J, Meseguer J, et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 2004 Jul; 59 (7): 766-71
45. Martinez-Cócera C, De Molina M, Marti-Guadaño E, et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Investig Allergol Clin Immunol 2005; 15 (1): 22-9
46. Maspero J, Fantin S, Bisbal C, et al. A 12-week placebo-controlled study of rupatadine 10mg once daily comparative with cetirizine 10mg once daily, in the treatment of persistent allergic rhinitis [abstract no. 758 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10-14; Vienna
47. Roger A, Arnáiz E, Valero A, et al. Rupatadine 10mg improves quality of life in long-term treatment of persistent allergic rhinitis [abstract no. 761 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10-14; Vienna
48. Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. In press
49. Giménez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. In press
50. Juniper EF, Thompson AK, Ferrie PJ, et al. Development and validation of the standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) [abstract no. 273]. J Allergy Clin Immunol 1999; 103 (1 Pt 2): S71
51. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19 (3): 210-6
52. E1: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. ICH Harmonised Tripartate Guideline. Current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [online]. Available from URL: http://www. ich.org/LOB/media/MEDIA435.pdf [Accessed 2006 Nov 23]
53. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/245502en.pdf [Accessed 2006 Nov 23]
54. Valero A, Rivas P, Castillo JA, et al. One year safety data of rupatadine 10mg in patients with allergic rhinitis [abstract no. 759 plus poster]. The XXV Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10-14; Vienna
55. Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002 Feb; 11 (2): 259-73
56. Baiardini I, Braido F, Cauglia S, et al. Sleep disturbances in allergic diseases. Allergy 2006 Nov; 61 (11): 1259-67
57. 1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005 Aug; 76 (2): 118-26
58. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26 (12): 863-93